Register Login

All Posts

FDA Approves Hemophilia A Gene Transfer Rx

Today, July 3, 2023, the FDA approved the use of BioMarin’s Roctavian® [valoctocogene roxaparvovec] for treating adults with severe hemophilia A without inhibitors. The FDA also approved BioMarin’s companion diagnostic, AAV5 DetectCDx, which identifies the patients most likely to benefit from Roctavian. Click here for the LinkedIn announcement. Click here for a provocative FirstWord PHARMA […]
read more

Coag Conversation Part 3: VWF and ADAMTS13: Cardiovascular Diseases

Introducing The Many Faces of von Willebrand Factor or, von Willebrand Factor, ADAMTS13, Malignancy and Beyond Part 3: von Willebrand Factor and ADAMTS13; Thrombotic Mechanisms and Cardiovascular Diseases. This 30″ talk features George A. Fritsma, MS, MLS, proprietor of The Fritsma Factor, Your Interactive Hemostasis Resource, and Emmanual Favaloro, PhD, Principal Hospital Scientist at the […]
read more